Actively Recruiting
Safety and Dose Finding Study of EVM16 Vaccine Alone or With Tislelizumab in Adults With Advanced or Recurrent Solid Tumors
Led by Peking University · Updated on 2026-06-22
78
Participants Needed
2
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, side effects, and effects of a cancer vaccine called EVM16, either alone or combined with an anti-PD-1 antibody named tislelizumab. The trial focuses on adults with advanced or recurring solid tumors who have not responded to standard treatments. The main goals include determining the safe dose of EVM16 and how it works when combined with tislelizumab. Participants receive different doses of EVM16 either by itself or together with tislelizumab. The study includes several groups three dose escalation levels for EVM16 alone and combined with tislelizumab, followed by a dose expansion phase using the recommended dose of EVM16 with tislelizumab. Treatment and observation can last up to approximately one year during which researchers monitor safety and effects. During the trial, participants undergo assessments to track safety and tolerability from their first treatment until 90 days after the last dose. Researchers also measure immune responses to EVM16 and evaluate tumor response, disease control, remission duration, time to remission, and progression-free survival. The study involves tissue sample collection for vaccine production and ongoing monitoring until disease progression or other endpoints, with total participation lasting up to about one year or more.
CONDITIONS
Brief Title
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
Research Team
L
Lin Shen, MD
Y
Yanshuo Cao, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here